Vanguard Group’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $25.8M | Buy |
16,016,448
+468,940
| +3% | +$982K | ﹤0.01% | 2502 |
|
|
2025
Q3 | $42.4M | Buy |
15,547,508
+936,042
| +6% | +$3.11M | ﹤0.01% | 2244 |
|
|
2025
Q2 | $53.2M | Buy |
14,611,466
+1,925,663
| +15% | +$5.29M | ﹤0.01% | 2090 |
|
|
2025
Q1 | $24.4M | Buy |
12,685,803
+1,801,603
| +17% | +$3.68M | ﹤0.01% | 2422 |
|
|
2024
Q4 | $20.7M | Buy |
10,884,200
+813,902
| +8% | +$1.41M | ﹤0.01% | 2571 |
|
|
2024
Q3 | $13.3M | Buy |
10,070,298
+794,035
| +9% | +$1.06M | ﹤0.01% | 2814 |
|
|
2024
Q2 | $9.46M | Buy |
9,276,263
+1,050,291
| +13% | +$1.3M | ﹤0.01% | 2967 |
|
|
2024
Q1 | $15.1M | Buy |
8,225,972
+618,500
| +8% | +$989K | ﹤0.01% | 2732 |
|
|
2023
Q4 | $9.43M | Buy |
7,607,472
+86,155
| +1% | +$87.9K | ﹤0.01% | 2977 |
|
|
2023
Q3 | $8.57M | Sell |
7,521,317
-289,744
| -4% | -$372K | ﹤0.01% | 2967 |
|
|
2023
Q2 | $7.15M | Sell |
7,811,061
-4,699,843
| -38% | -$4.54M | ﹤0.01% | 3134 |
|
|
2023
Q1 | $7.01M | Buy |
12,510,904
+1,272,034
| +11% | +$972K | ﹤0.01% | 3146 |
|
|
2022
Q4 | $6.48M | Sell |
11,238,870
-1,943,995
| -15% | -$609K | ﹤0.01% | 3169 |
|
|
2022
Q3 | $4.17M | Sell |
13,182,865
-3,076,239
| -19% | -$1.21M | ﹤0.01% | 3416 |
|
|
2022
Q2 | $5.74M | Buy |
16,259,104
+1,856,116
| +13% | +$779K | ﹤0.01% | 3302 |
|
|
2022
Q1 | $10.3M | Buy |
14,402,988
+1,167,319
| +9% | +$2.5M | ﹤0.01% | 3129 |
|
|
2021
Q4 | $29.9M | Buy |
13,235,669
+824,426
| +7% | +$2.25M | ﹤0.01% | 2633 |
|
|
2021
Q3 | $35.7M | Buy |
12,411,243
+255,524
| +2% | +$730K | ﹤0.01% | 2544 |
|
|
2021
Q2 | $46.1M | Buy |
12,155,719
+463,565
| +4% | +$1.56M | ﹤0.01% | 2419 |
|
|
2021
Q1 | $39.6M | Buy |
11,692,154
+3,257,395
| +39% | +$11.7M | ﹤0.01% | 2438 |
|
|
2020
Q4 | $23.6M | Buy |
8,434,759
+1,869,694
| +28% | +$5.46M | ﹤0.01% | 2554 |
|
|
2020
Q3 | $16.5M | Sell |
6,565,065
-755,811
| -10% | -$6.63M | ﹤0.01% | 2548 |
|
|
2020
Q2 | $99.4M | Buy |
7,320,876
+1,435,322
| +24% | +$14.8M | ﹤0.01% | 1680 |
|
|
2020
Q1 | $44.6M | Buy |
5,885,554
+365,374
| +7% | +$2.84M | ﹤0.01% | 1919 |
|
|
2019
Q4 | $34.9M | Buy |
5,520,180
+54,123
| +1% | +$257K | ﹤0.01% | 2277 |
|
|
2019
Q3 | $21.4M | Buy |
5,466,057
+296,126
| +6% | +$1.27M | ﹤0.01% | 2465 |
|
|
2019
Q2 | $25M | Sell |
5,169,931
-633,438
| -11% | -$3.6M | ﹤0.01% | 2401 |
|
|
2019
Q1 | $47.5M | Buy |
5,803,369
+896,018
| +18% | +$6.15M | ﹤0.01% | 2110 |
|
|
2018
Q4 | $27.1M | Buy |
4,907,351
+2,349,768
| +92% | +$18.4M | ﹤0.01% | 2304 |
|
|
2018
Q3 | $22.6M | Sell |
2,557,583
-17,771
| -0.7% | -$159K | ﹤0.01% | 2524 |
|
|
2018
Q2 | $25.7M | Buy |
2,575,354
+216,165
| +9% | +$2.16M | ﹤0.01% | 2456 |
|
|
2018
Q1 | $22.5M | Buy |
2,359,189
+417,987
| +22% | +$5.85M | ﹤0.01% | 2451 |
|
|
2017
Q4 | $28.9M | Buy |
1,941,202
+220,184
| +13% | +$3.65M | ﹤0.01% | 2334 |
|
|
2017
Q3 | $33.9M | Buy |
1,721,018
+284,855
| +20% | +$4.38M | ﹤0.01% | 2245 |
|
|
2017
Q2 | $20.6M | Buy |
1,436,163
+134,283
| +10% | +$1.7M | ﹤0.01% | 2443 |
|
|
2017
Q1 | $12M | Buy |
1,301,880
+105,645
| +9% | +$1.03M | ﹤0.01% | 2680 |
|
|
2016
Q4 | $12.5M | Buy |
1,196,235
+43,772
| +4% | +$377K | ﹤0.01% | 2645 |
|
|
2016
Q3 | $10.4M | Buy |
1,152,463
+67,070
| +6% | +$570K | ﹤0.01% | 2668 |
|
|
2016
Q2 | $8.12M | Buy |
1,085,393
+67,246
| +7% | +$587K | ﹤0.01% | 2746 |
|
|
2016
Q1 | $9.17M | Buy |
1,018,147
+328,865
| +48% | +$2.67M | ﹤0.01% | 2657 |
|
|
2015
Q4 | $8.9M | Buy |
689,282
+75,445
| +12% | +$770K | ﹤0.01% | 2700 |
|
|
2015
Q3 | $5.93M | Buy |
613,837
+120,208
| +24% | +$1.1M | ﹤0.01% | 2890 |
|
|
2015
Q2 | $5.08M | Buy |
493,629
+205,787
| +71% | +$1.76M | ﹤0.01% | 3015 |
|
|
2015
Q1 | $3.2M | Buy |
287,842
+56,517
| +24% | +$602K | ﹤0.01% | 3205 |
|
|
2014
Q4 | $2.69M | Buy |
231,325
+67,214
| +41% | +$964K | ﹤0.01% | 3173 |
|
|
2014
Q3 | $3.63M | Buy |
164,111
+16,237
| +11% | +$373K | ﹤0.01% | 3006 |
|
|
2014
Q2 | $4.11M | Buy |
+147,874
| New | +$3.56M | ﹤0.01% | 2947 |
|
Other funds holding AKBA
Vanguard Group's AKBA Position: Q4 2025 in Review
Vanguard Group increased its Akebia Therapeutics (AKBA) stake by 3% in Q4 2025, buying an estimated $982K and bringing the position to 16,016,448 shares worth $25.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2502.
Vanguard Group first reported a position in AKBA in Q2 2014 and has held it in 47 quarters since. The position peaked at $99.4M in Q2 2020. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.
- Vanguard Group held 16,016,448 shares of Akebia Therapeutics worth $25.8M as of Q4 2025.
- Vanguard Group bought 468,940 Akebia Therapeutics shares in Q4 2025, an estimated $982K.
- Akebia Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2502 holding.
- Vanguard Group first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 47 quarters since.
- Vanguard Group's Akebia Therapeutics position peaked at $99.4M in Q2 2020.
- 165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.